{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-352750","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2021-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.522727+00:00","generated_at":"2026-06-28T02:33:38.247381+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LianBio Q3 net loss narrows to $13.1M; completed $334.5M IPO","bullets":["Net loss of $13.1M ($0.63 per share) narrowed from $120.2M ($11.71) in Q3 2020.","R&D expenses fell to $4.7M from $116.9M; G&A increased to $8.9M from $2.1M.","Completed IPO raising $334.5M gross ($311.1M net); cash position sufficient through 2023.","Initiated PK study of mavacamten and Phase 2a trial of infigratinib in China.","Appointed Jesse Wu and Susan Silbermann to board; new chief scientific advisor and China GM."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-352750","json":"https://secwatch.observer/filing/0001193125-21-352750.json","markdown":"https://secwatch.observer/filing/0001193125-21-352750.md","text":"https://secwatch.observer/filing/0001193125-21-352750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/0001193125-21-352750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000119312521352750/d455505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:33:38.247381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}